Safe Emergency Department dIscharGe Rate (SEIGE)

Sponsor
Hennepin Healthcare Research Institute (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04772157
Collaborator
Siemens Healthineers (Other)
1,000
1
24
41.7

Study Details

Study Description

Brief Summary

The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at the point of care (POC) as well as in the clinical laboratory.

The Siemens POC High Sensitivity Troponin-I Test System is to be used as an aid in the diagnosis of myocardial infarction (MI).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Cardiac Troponin Testing

Detailed Description

Study purpose/objective:
  • Evaluate the clinical performance of the Siemens POC HS cTn-I test system for the diagnosis and rule out of AMI in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication.

  • Correlate the blood and plasma outcomes on the Siemens POC HS cTn-I test system as function of the corresponding hematocrit (Hct) values.

Hypothesis: The Siemens POC HS cTn-I Test System will offer an excellent diagnostic performance for acute myocardial injury and acute myocardial infarction, as well as expedite the risk stratification of patients for early discharge from the emergency department.

Study Design

Study Type:
Observational
Actual Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Safe Emergency Department dIscharGe Rate (SEIGE)
Actual Study Start Date :
Oct 13, 2020
Actual Primary Completion Date :
Oct 13, 2021
Anticipated Study Completion Date :
Oct 13, 2022

Arms and Interventions

Arm Intervention/Treatment
Cohort

Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.

Diagnostic Test: Cardiac Troponin Testing
Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.

Outcome Measures

Primary Outcome Measures

  1. Examine the incidence of undetectable(<LoD), measurable (LoD - 99th percentile), and increased (>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System [Day 1]

    Examine the incidence of undetectable(<LoD), measurable (LoD - 99th percentile), and increased (>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System in comparison to a high sensitivity cTnI assay (Abbott & Siemens Healthineers) to determine the potential impact on positivity rate, defined by sex-specific 99th percentiles.

  2. Examine Concordance [Day 1]

    Examine concordance (dis) between hs-cTnI in comparison to a high sensitivity (Abbott & Siemens Healthineers) cTnI assay

  3. Examine the diagnostic performance for acute myocardial injury and acute myocardial infarction [Day 1]

    Examine the diagnostic performance for a) acute myocardial injury and b) acute myocardial infarction based on various diagnostic strategies using hs-cTnI measurement(s), as follows: Single measurement strategies Limit of detection (LoD) Concentration threshold tailored to meet a clinical need: Derive an optimal rule-out ng/L cutoff for Siemens POC HS cTn-I Test System. Accelerated serial sampling (0/2h protocol) Using the both sex-specific and overall 99th percentiles Delta (absolute concentration serial change value, 0-2h) analysis

  4. Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs [Day 1]

    Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs, including patients categorized with acute myocardial injury and acute myocardial infarction, including type 1 and 2 myocardial infarction following the 4th Universal Definition of Myocardial Infarction.

  5. Impact on the incidence of myocardial injury and myocardial infarction diagnoses. [Day 1]

    Examine the potential impact on the incidence of myocardial injury and myocardial infarction diagnoses using hs-cTnI upon clinical practice implementation with a comparison to the hospital's final ICD-10 code diagnosis of type 1 and type 2 MIs.

Secondary Outcome Measures

  1. All-cause mortality [up to 30 days]

    any death

  2. Cardiac mortality [up to 30 days]

    death due to cardiac reasons

  3. Adjudicated index acute myocardial infarction according to 4th UDMI [on admission]

    acute myocardial infarction, including sub-types following the Fourth Universal Definition of Myocardial Infarction

  4. Safety Outcome - MACE [30 days]

    Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Presents to the ED, or ambulatory care center equivalent, with signs or symptoms suspicious of a possible ACS event.

  2. Baseline cTn-I measurement and one additional cTn-I measurement at two hours after the first measurement.

  3. At least one 12-lead electrocardiogram

Exclusion Criteria

  1. Less than 21 years old

  2. Pregnancy

  3. Trauma

  4. Declines to participate or has indicated that their blood/ medical information cannot be used for investigational purposes

  5. Did not present through the ED

  6. Transferred from an outside hospital or clinic.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hennepin Healthcare Research Institute / Hennepin County Medical Center Minneapolis Minnesota United States 55404

Sponsors and Collaborators

  • Hennepin Healthcare Research Institute
  • Siemens Healthineers

Investigators

  • Principal Investigator: Fred S Apple, PhD, Hennepin Healthcare Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hennepin Healthcare Research Institute
ClinicalTrials.gov Identifier:
NCT04772157
Other Study ID Numbers:
  • SEIGE
First Posted:
Feb 26, 2021
Last Update Posted:
Jan 31, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Hennepin Healthcare Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2022